Based on the Cytokinetics Inc stock forecast from 9 analysts, the average analyst target price for Cytokinetics Inc is USD 86.90 over the next 12 months. Cytokinetics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cytokinetics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Cytokinetics Inc’s stock price was USD 48.87. Cytokinetics Inc’s stock price has changed by +0.45% over the past week, -0.47% over the past month and +9.57% over the last year.
No recent analyst target price found for Cytokinetics Inc
No recent average analyst rating found for Cytokinetics Inc
Company Overview Cytokinetics Inc
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Read Less
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impac...Read More
Frequently Asked Questions About Cytokinetics Inc (CYTK) Stock
Based on ratings from 9 analysts Cytokinetics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 19 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on CYTK's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for CYTK is USD 86.90 over the next 12 months. The maximum analyst target price is USD 120 while the minimum anlayst target price is USD 60.
CYTK stock's Price/Earning ratio is 450.00.
Our analysis grades CYTK stock's Price / Earning ratio at F. This means that CYTK stock's Price/Earning ratio is above 96% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CYTK may be a overvalued for its sector.
The last closing price of CYTK's stock was USD 48.87.
The most recent market capitalization for CYTK is USD 5.98B.
Based on targets from 9 analysts, the average taret price for CYTK is projected at USD 86.90 over the next 12 months.
This means that CYTK's stock price may go up by +77.83% over the next 12 months.
We can't find any ETFs which contains Cytokinetics Inc's stock.
As per our most recent records Cytokinetics Inc has 423 Employees.
Cytokinetics Inc's registered address is 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Cytokinetics Inc's website at https://www.cytokinetics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Cytokinetics Inc (CYTK) Stock
Based on ratings from 9 analysts Cytokinetics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 19 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on CYTK's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for CYTK is USD 86.90 over the next 12 months. The maximum analyst target price is USD 120 while the minimum anlayst target price is USD 60.
CYTK stock's Price/Earning ratio is 450.00.
Our analysis grades CYTK stock's Price / Earning ratio at F. This means that CYTK stock's Price/Earning ratio is above 96% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CYTK may be a overvalued for its sector.
The last closing price of CYTK's stock was USD 48.87.
The most recent market capitalization for CYTK is USD 5.98B.
Based on targets from 9 analysts, the average taret price for CYTK is projected at USD 86.90 over the next 12 months.
This means that CYTK's stock price may go up by +77.83% over the next 12 months.
We can't find any ETFs which contains Cytokinetics Inc's stock.
As per our most recent records Cytokinetics Inc has 423 Employees.
Cytokinetics Inc's registered address is 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Cytokinetics Inc's website at https://www.cytokinetics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CYTK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
